We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Rit Capital Partners Plc | LSE:RCP | London | Ordinary Share | GB0007366395 | ORD �1 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
34.00 | 1.90% | 1,820.00 | 1,816.00 | 1,822.00 | 1,820.00 | 1,790.00 | 1,790.00 | 55,354 | 10:17:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Unit Inv Tr, Closed-end Mgmt | 108.8M | 66.1M | 0.4508 | 40.02 | 2.65B |
TIDMRCP
RNS Number : 2611M
RIT Capital Partners PLC
26 April 2018
RIT CAPITAL PARTNERS PLC (LEI: P31Q1NLTW35JJGHA4667)
26 April 2018
Election of Directors
Following the passing of all resolutions by shareholders at its Annual General Meeting, RIT Capital Partners plc ('RIT') announces the following elections to the Board with immediate effect:
André Perold
André Perold has been elected to the Board as a Non-Executive Director. Mr Perold is a Co-Founder, Managing Partner and Chief Investment Officer of HighVista Strategies, a Boston based investment firm. He is a board member of the Vanguard Group, the global investment company and also serves on the Investment Committee of the Partners Healthcare System.
Mr Perold will sit on the Audit & Risk Committee.
There are no other details that require to be disclosed in respect of the appointment of Mr Perold pursuant to Rule 9.6.13 of the UK Listing Rules.
Jeremy Sillem
Jeremy Sillem has been elected to the Board as a Non-Executive Director. Mr Sillem is Managing Partner and Founder of Spencer House Partners LLP, which provides corporate finance advice to asset and wealth management businesses. From 2000 to 2004 he was Executive Chairman of Bear Stearns International in London, prior to which he had a 28-year career with Lazard in London and New York.
Mr Sillem will sit on the Audit & Risk Committee.
Mr Sillem is currently a director of Biopharma Credit PLC. There are no other details that require to be disclosed in respect of the appointment of Mr Sillem pursuant to Rule 9.6.13 of the UK Listing Rules.
Composition of Board Committee
Phillipe Costeletos has been appointed as a member of the Remuneration Committee of RIT, with immediate effect.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAFQLFLVZFZBBB
(END) Dow Jones Newswires
April 26, 2018 07:41 ET (11:41 GMT)
1 Year Rit Capital Partners Chart |
1 Month Rit Capital Partners Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions